Note: Ingredients listed on restricted chemical lists
EC/CAS
9005-25-8
Name of the chemical
Starch
Concentration
>75
EC/CAS
27668-52-6
Name of the chemical
Dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride
Concentration
<1
EC/CAS
14808-60-7
Name of the chemical
Silica, crystalline
Concentration
<1
EC/CAS
24937-78-8
Name of the chemical
ethylene-vinyl acetate copolymer wax
Concentration
<1
General Information
Revision date
2003-10-07
Product name
USG Acoustical Ceiling Panels and Tiles - ECLIPSE ClimaPlus with Aegis Microbe Shield
Product Synonyms
Mineral wool acoustical ceiling panels
Chemical name
Mixture of slag wool and minerals. Ceiling panels and tiles are products considered not to be
Manufacturer Name
USG Interiors, Inc
Emergency telephone
1 (800) 507-8899
Icons in SDS
Company Information
company name
USG Interiors, Inc
Section 2
SECTION 2: Hazards identification
INFORMATION FOR HANDLING AND IDENTIFICATION OF CHEMICAL HAZARDS
NFPA Ratings
HEALTH 0 0 = Minimal Hazard HIMS Ratings: * 1 = Slight Hazard FLAMMABILITY 0 Health: 0 Health: *0 2 = Moderate Hazard Fire: 0 Fire: 0 PHYSICAL HAZARD 0 3 = Serious Hazard Reactivity: 0 Reactivity: 0 PERSONAL PROTECTION E 4 = Severe Hazard Personal Protection: Use eye protection. Use gloves and NIOSH/MSHA-approved respiratory protection when required. *Respirable crystalline silica can cause lung disease and/or cancer. EMERGENCY OVERVIEW This product is not expected to produce any unusual hazards during normal use. Exposure to high dust levels may irritate the skin, eyes, nose, throat, or upper respiratory tract. Man-made mineral fibres have been classified by the European Union as irritating to skin (R:38).
Potential health effects
ACUTE: The components of acoustical ceiling panels and tiles are bound in a cementitious matrix. When panels are cut or trimmed, especially with power tools, the resulting dust may cause transitory mechanical irritation to skin, eyes or respiratory tract. Eyes: Airborne dust or direct contact can cause mechanical irritation of eyes. If burning, redness, itching, pain or other symptoms persist or develop, consult physician. Skin: Direct, prolonged or repeated contact with the skin can cause temporary irritation and itchiness. Rubbing of this product against the skin can result in abrasions. If irritation persists, consult a physician. Inhalation: Inhalation of dust can irritate the nose, throat, and the upper respiratory tract. Persons subjected to large amounts of this dust will be forced to leave area because of nuisance conditions such as coughing, sneezing and nasal irritation. Labored breathing may occur after excessive inhalation. If respiratory symptoms persist, consult physician. Ingestion: Unlikely to occur, but if ingested may cause temporary irritation to the gastrointestinal tract, especially the throat and stomach. CHRONIC: Inhalation: Prolonged and repeated exposure to airborne free respirable crystalline silica can result in lung disease (i.e., silicosis) and/or lung cancer. The development of silicosis may increase the risks of additional health effects. The risk of developing silicosis is dependent upon the exposure intensity and duration. Exposures to respirable crystalline silica are not expected during the normal use of this product; however, actual levels must be determined by workplace hygiene testing. The concentration of respirable crystalline silica measured in airborne dust samples was below the detection limit using NIOSH Method 7500 in industrial hygiene testing of workers installing USG Acoustical Ceiling Panels for an 8 hour work day. Slag wool fiber has been classified as “not classifiable as to its carcinogenicity to humans” (Group 3) by the International Agency for Research on Cancer (IARC). SECTION 3 HAZARD IDENTIFICATION (continued) CHRONIC (continued): Eyes: No known effects Skin: No known effects. Ingestion: No known effects. TARGET ORGANS: Eyes, skin and nose, throat & respiratory system.
Principle Routes of Exposure
Inhalation, eyes and skin contact MEDICAL CONDITIONS WHICH MAY BE AGGRAVATED: Pre-existing upper respiratory and lung diseases such as, but not limited to, bronchitis, emphysema and asthma. Pre-existing skin diseases such as, but not limited to, rashes and dermatitis.